A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production

Annals of Surgery

Volumn 257, Issue 5, 2013, Pages 952-960

  Lee, Hyun Joo ^a,b   Yang, Heung Mo ^c   Choi, Young Sil ^a   Park, Sang Hoon ^d   Moon, Sung Hwan ^e   Lee, Yong Soo ^a   Sung, Young Chul ^d   Kim, Sung Joo ^b,c  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Pohang University of Science and Technology (POSTECH)   (South Korea)

^e CHA Stem Cell Institute   (South Korea)

Author keywords

adenoviral transduction; human adipose tissue derived mesenchymal stromal cells (hAD MSCs); malignant fibrous histiocytoma (MFH); metastasis; tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL)

Indexed keywords

CASPASE 8; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE MODEL; EXPLANT; HUMAN; IN VITRO STUDY; MALIGNANT FIBROUS HISTIOCYTOMA; MESENCHYMAL STROMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR XENOGRAFT;

ADIPOSE TISSUE, WHITE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; FLOW CYTOMETRY; GENETIC THERAPY; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; NEOPLASM METASTASIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 84876296096     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182710401     Document Type: Article

References (45)

1. Matushansky I, Charytonowicz E, Mills J, et al. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century. Expert Rev Anticancer Ther. 2009;9:1135-1144.
2. Al-Agha OM, Igbokwe AA. Malignant fibrous histiocytoma: between the past and the present. Arch Pathol Lab Med. 2008;132:1030-1035.
3. Pobirci DD, Bogdan F, Pobirci O, et al. Study of malignant fibrous histio-cytoma: clinical, statistic and histopathological interrelation. Rom J Morphol Embryol. 2011;52:385-388.
4. Bucerius J, Buchholz B, Biersack HJ, et al. Avoidance of invasive diagnostic and harmful therapeutic measures in a patient with malignant fibrous histiocytoma and extensive clinically occult metastases. Natl Med Assoc. 2009;101:953-955.
5. Menon LG, Kelly K, Yang HW, et al. Human bone marrow-derived mesenchy-mal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells. 2009;27:2320-2330.
6. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA. 2009;106:4822-4827.
7. Hamada H, Kobune M, Nakamura K, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 2005;96:149-156.
8. Nakamizo A, Marini F, Lang FF, et al. Human bone marrow-derived mes-enchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65:3307-3318.
9. Kim SM, Lim JY, Park SI, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008;68:9614-9623.
10. Kim SM, Oh JH, Park SA, et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells. 2010;28:2217-2228.
11. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchy-mal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603-3608.
12. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593-1603.
13. Xin H, Kanehira M, Mizuguchi H, et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells. 2007;25:1618-1626.
14. Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007;67:6304-6313.
15. Abumaree M, Al Jumah M, Kalionis B, et al. Immunosuppressive Properties of Mesenchymal Stem Cells. Stem Cell Rev. 2012;8:375-392.
16. Mahalingam D, Szegezdi E, Keane M, et al. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 2009;35:280-288.
17. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol. 2005;23:9394-9407.
18. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27:6207-6215.
19. Wang S, Ren W, Liu J, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010;16:2591-2604.
20. Picarda G, Lamoureux F, Geffroy L, et al. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res. 2010;16:2363-2374.
21. Takahashi K, Sato K. Establishment and characterization of a human neoplastic cell line (MFH-ino) derived from malignant fibrous histiocytoma of maxilla. Hum Cell. 1991;4:51-57.
22. Yang HM, Cho MR, Kim SJ, et al. The effect of human fetal liver-derived mesenchymal stem cells on CD34+ hematopoietic stem cell repopulation in NOD/Shi-scid/IL-2Ra(null) mice. Transplant Proc. 2011;43:2004-2008.
23. Yang HM, Sung JH, Kim SJ, et al. Enhancement of the immunosuppressive effect of human adipose tissue-derived mesenchymal stromal cells through HLA-G1 expression. Cytotherapy. 2011;14:70-79.
24. Jin HT, Youn JI, Kim HJ, et al. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther. 2005;16:328-338.
25. Youn JI, Park SH, Jin HT, et al. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. Cancer Gene Ther. 2008;15:703-712.
26. Park SH, Doh J, Park SI, et al. Branched oligomerization of cell-permeable peptides markedly enhances the transduction efficiency of adenovirus into mesenchymal stem cells. Gene Ther. 2010;17:1052-1061.
27. Hwang SS, Park SY, Park YH. The CT and F-FDG PET/CT appearance of primary renal malignant fibrous histiocytoma. J Med Imaging Radiat Oncol. 2010;54:365-367.
28. Charest M, Hickeson M, Turcotte RE, et al. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009;36:1944-1951.
29. Grisendi G, Bussolari R, Cafarelli L, et al. Adipose-derived mesenchy-mal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010;70:3718-3729.
30. Merchant MS, Yang X, Melchionda F, et al. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res. 2004;64:8349-8356.
31. Aust L, Devlin B, Foster SJ, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy. 2004;6:7-14.
32. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211-228.
33. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8:573-587.
34. Yoo JW, Lee DH, Song HJ, et al. Peritoneal dissemination from malignant fibrous histiocytoma of the buttock: unusual metastases from a rare tumor. Gut Liver. 2008;2:213-215.
35. Loebinger MR, Eddaoudi A, Davies D, et al. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69:4134-4142.
36. Mohr A, Albarenque SM, Deedigan L, et al. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells. 2010;28:2109-2120.
37. Klopp AH, Gupta A, Spaeth E, et al. Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11-19.
38. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-563.
39. Zhang Y. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009;69:5259-5266.
40. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med. 2006;203:1235-1247.
41. Otsu K, Das S, Bhattacharya J, et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood. 2009;113:4197-4205.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
43. Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-aspartate receptor for chronic pain management: preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage Rev. 2000;20:358-373.
44. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in trans-lational biomedical research. Nat Rev Immunol. 2007;7:118-130.
45. Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes. 2010;17:120-125.